Literature DB >> 10229805

Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

V Bronte1, D B Chappell, E Apolloni, A Cabrelle, M Wang, P Hwu, N P Restifo.   

Abstract

Tumor cells gene-modified to produce GM-CSF potently stimulate antitumor immune responses, in part, by causing the growth and differentiation of dendritic cells (DC). However, GM-CSF-modified tumor cells must be gamma-irradiated or they will grow progressively, killing the host. We observed that 23 of 75 (31%) human tumor lines and two commonly used mouse tumor lines spontaneously produced GM-CSF. In mice, chronic GM-CSF production by tumors suppressed Ag-specific CD8+ T cell responses. Interestingly, an inhibitory population of adherent CD11b(Mac-1)/Gr-1 double-positive cells caused the observed impairment of CD8+ T cell function upon direct cell-to-cell contact. The inhibitory cells were positive for some markers associated with Ag presenting cells, like F4/80, but were negative for markers associated with fully mature DC like DEC205, B7. 2, and MHC class II. We have previously reported that a similar or identical population of inhibitory "immature" APC was elicited after immunization with powerful recombinant immunogens. We show here that these inhibitory cells can be elicited by the administration of recombinant GM-CSF alone, and, furthermore, that they can be differentiated ex vivo into "mature" APC by the addition of IL-4 and GM-CSF. Thus, tumors may be able to escape from immune detection by producing "unopposed" GM-CSF, thereby disrupting the balance of cytokines needed for the maturation of fully functional DC. Further, CD11b/Gr-1 double-positive cells may function as "inhibitory" APC under the influence of GM-CSF alone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229805      PMCID: PMC2228333     

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  GM-CSF secretion in primary cultures of normal and cancerous human renal cells.

Authors:  N D Stephens; S L Barton; A Y Smith; R W Paul; J A Neidhart; J K Griffith
Journal:  Kidney Int       Date:  1996-09       Impact factor: 10.612

2.  Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.

Authors:  H I Levitsky; J Montgomery; M Ahmadzadeh; K Staveley-O'Carroll; F Guarnieri; D L Longo; L W Kwak
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

3.  A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production.

Authors:  V Kronin; K Winkel; G Süss; A Kelso; W Heath; J Kirberg; H von Boehmer; K Shortman
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

4.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

Authors:  D I Gabrilovich; H L Chen; K R Girgis; H T Cunningham; G M Meny; S Nadaf; D Kavanaugh; D P Carbone
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

5.  Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients.

Authors:  F Fu; Y Li; S Qian; L Lu; F Chambers; T E Starzl; J J Fung; A W Thomson
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

6.  Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes.

Authors:  L Lu; D McCaslin; T E Starzl; A W Thomson
Journal:  Transplantation       Date:  1995-12-27       Impact factor: 4.939

7.  Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface.

Authors:  O W Rokhlin; T L Griebling; N V Karassina; M A Raines; M B Cohen
Journal:  Anticancer Res       Date:  1996 Mar-Apr       Impact factor: 2.480

8.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

9.  A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis.

Authors:  G Süss; K Shortman
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

10.  Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.

Authors:  E Maraskovsky; K Brasel; M Teepe; E R Roux; S D Lyman; K Shortman; H J McKenna
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  142 in total

1.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 3.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 4.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 5.  Microbiota modulation of myeloid cells in cancer therapy.

Authors:  Romina S Goldszmid; Amiran Dzutsev; Sophie Viaud; Laurence Zitvogel; Nicholas P Restifo; Giorgio Trinchieri
Journal:  Cancer Immunol Res       Date:  2015-02       Impact factor: 11.151

Review 6.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Gammadelta T-cells: potential regulators of the post-burn inflammatory response.

Authors:  Martin G Schwacha
Journal:  Burns       Date:  2008-10-31       Impact factor: 2.744

8.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

Authors:  Carmela De Santo; Paolo Serafini; Ilaria Marigo; Luigi Dolcetti; Manlio Bolla; Piero Del Soldato; Cecilia Melani; Cristiana Guiducci; Mario P Colombo; Manuela Iezzi; Piero Musiani; Paola Zanovello; Vincenzo Bronte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 9.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.